Physician profile
Jules Sleiman
NPI 1407264468
$578.07
in general payments reported to CMS, 2019-2025
12 companies · $37.17 in 2025
The $37.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $127 · 2021: $117 · 2022: $41.93 · 2024: $57.03 · 2025: $37.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.43 · Education: $14.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.43 |
| Education | $14.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $155.76 | 2019-2025 | |
| Novo Nordisk INC | $94.98 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $91.79 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $50.53 | 2019 | |
| Glaxosmithkline, LLC. | $48.12 | 2019-2022 | |
| Abbvie INC. | $34.54 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.06 | 2024 | Gvoke Hypopen |
| Organon LLC | $18.69 | 2021 | |
| Exact Sciences Corporation | $15.47 | 2025 | The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $15.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.77 | 2024 | |
| Bardy Diagnostics, INC. | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jules Sleiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.